Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV...
33
Transcript of Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV...
![Page 1: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/1.jpg)
![Page 2: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/2.jpg)
![Page 3: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/3.jpg)
![Page 4: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/4.jpg)
![Page 5: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/5.jpg)
![Page 6: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/6.jpg)
![Page 7: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/7.jpg)
![Page 8: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/8.jpg)
![Page 9: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/9.jpg)
![Page 10: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/10.jpg)
![Page 11: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/11.jpg)
![Page 12: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/12.jpg)
![Page 13: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/13.jpg)
![Page 14: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/14.jpg)
![Page 15: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/15.jpg)
![Page 16: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/16.jpg)
![Page 17: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/17.jpg)
![Page 18: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/18.jpg)
![Page 19: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/19.jpg)
![Page 20: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/20.jpg)
![Page 21: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/21.jpg)
![Page 22: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/22.jpg)
![Page 23: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/23.jpg)
![Page 24: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/24.jpg)
![Page 25: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/25.jpg)
![Page 26: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/26.jpg)
![Page 27: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/27.jpg)
![Page 28: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/28.jpg)
![Page 29: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/29.jpg)
![Page 30: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/30.jpg)
![Page 31: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/31.jpg)
![Page 32: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/32.jpg)
![Page 33: Treatment of the high CV risk patients: Current global ... · Primary Prevention Trial Reduce CV Events ASCOT-I-LA: Secondary End Points 10,305 hypertensive patients randomized to](https://reader030.fdocuments.net/reader030/viewer/2022040617/5f1c3f5e181a075cce4e7092/html5/thumbnails/33.jpg)